ReviewOpen biology2026
The biology and pathophysiology of the proatherogenic metalloprotease ADAMTS7.
Review in Open biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The ADAMTS (a disintegrin and metalloproteinase with thrombospondin type-1 motifs) metalloprotease family comprises 19 members, and they play critical roles in development, angiogenesis and coagulation. These enzymes are also pivotal in the turnover of extracellular matrix proteins in various tissues, and their dysregulation has been linked to diseases such as arthritis, atherosclerosis, cancer and inflammation. These secreted zinc metalloproteases are composed of multiple domains and are localized to the extracellular matrix and present in circulation. The metalloprotease member 7 of this family or ADAMTS7 was cloned in 2004. However, in 2011, it gained significant attention when its gene locus was associated with an increased risk of atherosclerosis and coronary artery disease. Despite its strong association with human diseases, the biological functions, substrate targets and processing of ADAMTS7 remain poorly understood, limiting our comprehension of its roles in both health and disease. This review highlights the structural organization of ADAMTS7, its expression and regulation, known substrates, and its involvement in various pathophysiological processes. Additionally, perspectives on future research directions and priorities are presented. ADAMTS7 remains a compelling target for drug and biomarker discovery, though much about this metalloprotease remains to be uncovered.
Indexed as
Identifiers
41920022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.